Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach

被引:11
|
作者
Ahmad, Sajjad [1 ]
Waheed, Yasir [1 ]
Ismail, Saba [1 ]
Najmi, Muzammil Hasan [1 ]
Ansari, Jawad Khaliq [1 ]
机构
[1] Fdn Univ Islamabad, Med Coll, Fdn Univ, Islamabad, Pakistan
关键词
SARS-CoV-2; M-Pro; COVID-19; ASINEX antiviral library; MD simulation; MM-PBSA; WaterSwap; PERSPECTIVE; METABOLISM; ABSORPTION; EXCRETION; TOXICITY; SYSTEM;
D O I
10.1016/j.molliq.2021.115636
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a novel coronavirus and the etiological agent of global pandemic coronavirus disease (COVID-19) requires quick development of potential therapeutic strategies. Computer aided drug design approaches are highly efficient in identifying promising drug candidates among an available pool of biological active antivirals with safe pharmacokinetics. The main protease (M-Pro) enzyme of SARS-CoV-2 is considered key in virus production and its crystal structures are available at excellent resolution. This marks the enzyme as a good starting receptor to conduct an extensive structure-based virtual screening (SBVS) of ASINEX antiviral library for the purpose of uncovering valuable hits against SARS-CoV-2 M-Pro. A compound hit (BBB_26580140) was stand out in the screening process, as opposed to the control, as a potential inhibitor of SARS-CoV-2 M-Pro based on a combined approach of SBVS, drug likeness and lead likeness annotations, pharmacokinetics, molecular dynamics (MD) simulations, and end point MM-PBSA binding free energy methods. The lead was further used in ligand-based similarity search (LBSS) that found 33 similar compounds from the ChEMBL database. A set of three compounds (SCHEMBL12616233, SCHEMBL18616095, and SCHEMBL20148701), based on their binding affinity for M-Pro, was selected and analyzed using extensive MD simulation, hydrogen bond profiling, MM-PBSA, and WaterSwap binding free energy techniques. The compounds conformation with M-Pro show good stability after initial within active cavity moves, a rich intermolecular network of chemical interactions, and reliable relative and absolute binding free energies. Findings of the study suggested the use of BBB_26580140 lead and its similar analogs to be explored in vivo which might pave the path for rational drug discovery against SARS-CoV-2 M-Pro. (C) 2021 Elsevier B.V. All rights reserved.
引用
收藏
页数:13
相关论文
共 48 条
  • [1] In-Silico Investigation on Chloroquine Derivatives: A Potential Anti-COVID-19 Main Protease
    Latona, Dayo Felix
    Mutiu, Oluwatumininu Abosede
    Adeoye, Moriam Dasola
    Oyebamiji, Abel Kolawole
    Akintelu, Sunday Adewale
    Adedapo, Adeyinka S.
    BIOINTERFACE RESEARCH IN APPLIED CHEMISTRY, 2022, 12 (06): : 8492 - 8501
  • [2] In silico identification of potent FDA approved drugs against Coronavirus COVID-19 main protease: A drug repurposing approach
    Chandel, Vaishali
    Raj, Sibi
    Rathi, Brijesh
    Kumar, Dhruv
    CHEMICAL BIOLOGY LETTERS, 2020, 7 (03): : 166 - 175
  • [3] Isolation and In Silico Anti-COVID-19 Main Protease (Mpro) Activities of Flavonoids and a Sesquiterpene Lactone from Artemisia sublessingiana
    Jalmakhanbetova, Roza I.
    Suleimen, Yerlan M.
    Oyama, Masayoshi
    Elkaeed, Eslam B.
    Eissa, Ibrahim. H.
    Suleimen, Raigul N.
    Metwaly, Ahmed M.
    Ishmuratova, Margarita Yu.
    JOURNAL OF CHEMISTRY, 2021, 2021
  • [4] In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors
    Mahmoud A. A. Ibrahim
    Alaa H. M. Abdelrahman
    Khaled S. Allemailem
    Ahmad Almatroudi
    Mahmoud F. Moustafa
    Mohamed-Elamir F. Hegazy
    The Protein Journal, 2021, 40 : 296 - 309
  • [5] In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors
    Ibrahim, Mahmoud A. A.
    Abdelrahman, Alaa H. M.
    Allemailem, Khaled S.
    Almatroudi, Ahmad
    Moustafa, Mahmoud F.
    Hegazy, Mohamed-Elamir F.
    PROTEIN JOURNAL, 2021, 40 (03): : 296 - 309
  • [6] In silico Approach on Ribavirin Inhibitors for COVID-19 Main Protease
    Dhumad, Adil Muala
    Majeed, Hatem Jameel
    Harismah, Kun
    Zandi, Hasan
    BIOINTERFACE RESEARCH IN APPLIED CHEMISTRY, 2021, 11 (06): : 13924 - 13933
  • [7] Repurposing FDA-approved drugs for COVID-19: targeting the main protease through multi-phase in silico approach
    Metwaly, Ahmed M.
    Elkaeed, Eslam B.
    Alsfouk, Aisha A.
    Ibrahim, Ibrahim M.
    Elkady, Hazem
    Eissa, Ibrahim H.
    ANTIVIRAL THERAPY, 2024, 29 (06)
  • [8] Multi-Step In Silico Discovery of Natural Drugs against COVID-19 Targeting Main Protease
    Elkaeed, Eslam B.
    Youssef, Fadia S.
    Eissa, Ibrahim H.
    Elkady, Hazem
    Alsfouk, Aisha A.
    Ashour, Mohamed L.
    El Hassab, Mahmoud A.
    Abou-Seri, Sahar M.
    Metwaly, Ahmed M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
  • [9] An in-silico evaluation of COVID-19 main protease with clinically approved drugs
    Tachoua, Wafa
    Kabrine, Mohamed
    Mushtaq, Mamona
    Ul-Haq, Zaheer
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2020, 101 (101):
  • [10] In Silico Screening of Some Anti-Cancer Drugs Against the Main Protease of COVID-19 Using Molecular Docking
    Ouni, Leila
    Ramazani, Ali
    LETTERS IN ORGANIC CHEMISTRY, 2023, 20 (01) : 77 - 90